Eric Jonasch, MD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses significant developments in renal cell carcinoma (RCC) over the last several years. He specifically focuses on the incorporation of immune checkpoint inhibitors into the frontline treatment of RCC and the emergence of HIF-2α inhibitors, such as belzutifan (Welireg).
Targeted neoadjuvant therapy for high-complexity cases of renal masses in a solitary kidney
September 2nd 2023A Cleveland Clinic study found that TKIs in the neoadjuvant setting are associated with greater use of partial nephrectomy when treating patients diagnosed with renal masses in a solitary kidney.
Adjuvant pembrolizumab DFS benefit in ccRCC sustained across disease subgroups
August 31st 2023The disease-free survival and distant metastasis-free survival benefits observed with adjuvant pembrolizumab in the intent-to-treat population of patients with clear cell renal cell carcinoma extended across all subgroups defined by disease risk, tumor stage, and lymph node involvement.
2 Clarke Drive
Cranbury, NJ 08512